Cargando…
Injectable Biodegradable Silica Depot: Two Months of Sustained Release of the Blood Glucose Lowering Peptide, Pramlintide
Diabetes mellitus is a major healthcare challenge. Pramlintide, a peptide analogue of the hormone amylin, is currently used as an adjunct with insulin for patients who fail to achieve glycemic control with only insulin therapy. However, hypoglycemia is the dominant risk factor associated with such a...
Autores principales: | Tyagi, Puneet, Koskinen, Mika, Mikkola, Jari, Sarkhel, Sanjay, Leino, Lasse, Seth, Asha, Madalli, Shimona, Will, Sarah, Howard, Victor G., Brant, Helen, Corkill, Dominic |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8952239/ https://www.ncbi.nlm.nih.gov/pubmed/35335929 http://dx.doi.org/10.3390/pharmaceutics14030553 |
Ejemplares similares
-
Sustained In-Vivo Release of Triptorelin Acetate from a Biodegradable Silica Depot: Comparison to Pamorelin(®) LA
por: Forsback, Ari-Pekka, et al.
Publicado: (2021) -
Pramlintide, an antidiabetic, is antineoplastic in colorectal cancer and synergizes with conventional chemotherapy
por: Al-Keilani, Maha S, et al.
Publicado: (2018) -
The effect of pramlintide, an antidiabetic amylin analogue, on angiogenesis-related markers in vitro
por: Safaeian, Leila, et al.
Publicado: (2020) -
Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming
por: Yang, Yuanzheng, et al.
Publicado: (2022) -
Study of forced degradation behavior of pramlintide acetate by HPLC and LC–MS
por: Yuan, Yu, et al.
Publicado: (2017)